Israel Englander’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-142,050
| Closed | -$1.05M | – | 6157 |
|
|
2026
Q1 | $1.05M | Buy |
+142,050
| New | +$924K | ﹤0.01% | 4354 |
|
|
2025
Q3 | – | Sell |
-25,677
| Closed | -$118K | – | 6271 |
|
|
2025
Q2 | $118K | Sell |
25,677
-5,703
| -18% | -$24.4K | ﹤0.01% | 5493 |
|
|
2025
Q1 | $153K | Sell |
31,380
-11,957
| -28% | -$72.6K | ﹤0.01% | 5357 |
|
|
2024
Q4 | $291K | Sell |
43,337
-6,086
| -12% | -$45.3K | ﹤0.01% | 5086 |
|
|
2024
Q3 | $382K | Sell |
49,423
-13,428
| -21% | -$81K | ﹤0.01% | 5034 |
|
|
2024
Q2 | $377K | Sell |
62,851
-18,846
| -23% | -$143K | ﹤0.01% | 4775 |
|
|
2024
Q1 | $737K | Sell |
81,697
-211,059
| -72% | -$1.92M | ﹤0.01% | 4546 |
|
|
2023
Q4 | $2.77M | Sell |
292,756
-47,455
| -14% | -$417K | ﹤0.01% | 3325 |
|
|
2023
Q3 | $4.05M | Sell |
340,211
-33,900
| -9% | -$601K | ﹤0.01% | 2898 |
|
|
2023
Q2 | $9.17M | Buy |
374,111
+120,401
| +47% | +$3.13M | ﹤0.01% | 2108 |
|
|
2023
Q1 | $7.94M | Sell |
253,710
-35,940
| -12% | -$2.08M | ﹤0.01% | 2186 |
|
|
2022
Q4 | $20.4M | Sell |
289,650
-6,577
| -2% | -$488K | 0.01% | 1433 |
|
|
2022
Q3 | $25.5M | Buy |
296,227
+21,332
| +8% | +$2.07M | 0.02% | 1125 |
|
|
2022
Q2 | $22.7M | Buy |
274,895
+182,689
| +198% | +$16.1M | 0.01% | 1190 |
|
|
2022
Q1 | $15.3M | Buy |
92,206
+53,142
| +136% | +$7.63M | 0.01% | 1661 |
|
|
2021
Q4 | $6.53M | Buy |
39,064
+37,736
| +2,842% | +$4.26M | ﹤0.01% | 2624 |
|
|
2021
Q3 | $115K | Sell |
1,328
-78,808
| -98% | -$5.22M | ﹤0.01% | 6376 |
|
|
2021
Q2 | $4.35M | Buy |
80,136
+2,108
| +3% | +$120K | ﹤0.01% | 2937 |
|
|
2021
Q1 | $4.65M | Sell |
78,028
-14,588
| -16% | -$853K | ﹤0.01% | 2650 |
|
|
2020
Q4 | $4.83M | Buy |
92,616
+27,503
| +42% | +$1.53M | ﹤0.01% | 2476 |
|
|
2020
Q3 | $3.15K | Sell |
65,113
-20,775
| -24% | -$994K | ﹤0.01% | 2231 |
|
|
2020
Q2 | $4.45M | Buy |
85,888
+72,719
| +552% | +$3.67M | 0.01% | 1883 |
|
|
2020
Q1 | $574K | Buy |
13,169
+10,868
| +472% | +$442K | ﹤0.01% | 2800 |
|
|
2019
Q4 | $92K | Buy |
2,301
+795
| +53% | +$24.5K | ﹤0.01% | 4039 |
|
|
2019
Q3 | $49K | Sell |
1,506
-4,716
| -76% | -$228K | ﹤0.01% | 4046 |
|
|
2019
Q2 | $480K | Buy |
+6,222
| New | +$968K | ﹤0.01% | 3266 |
|
|
2018
Q4 | – | Sell |
-5,463
| Closed | -$1.17M | – | 3969 |
|
|
2018
Q3 | $1.17M | Sell |
5,463
-2,052
| -27% | -$358K | ﹤0.01% | 2784 |
|
|
2018
Q2 | $1.3M | Buy |
+7,515
| New | +$1.31M | ﹤0.01% | 2678 |
|
Israel Englander's KZR Position: Q2 2026 in Review
Israel Englander sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 142,050 shares — an estimated $1.05M sold.
Israel Englander first reported a position in KZR in Q2 2018 and held it in 28 quarters. The position peaked at $25.5M in Q3 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Israel Englander reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Israel Englander sold 142,050 Kezar Life Sciences shares in Q2 2026, an estimated $1.05M.
- Israel Englander first reported a position in Kezar Life Sciences in Q2 2018 and held it in 28 quarters.
- Israel Englander's Kezar Life Sciences position peaked at $25.5M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.